Submission for OMB Review; 30-Day Comment Request: National Institute on Drug Abuse (NIDA) Summer Research Internship Program, 78987-78988 [2022-27990]
Download as PDF
<![CDATA[
78987
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Health, 5601 Fishers Lane, Room 4F30,
Rockville, MD 20892 (Virtual Meeting).
Open: 1:00 p.m. to 4:00 p.m.
Agenda: Report of Division Director and
Division Staff.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 4F30,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Kelly Y. Poe, Ph.D., Acting
Director, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 4F50, Bethesda, MD
20892, 301–496–7291, poeky@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice at least 10 days in advance of the
meeting. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.niaid.nih.gov/about/advisory-council,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27955 Filed 12–22–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request: National Institute
on Drug Abuse (NIDA) Summer
Research Internship Program
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: National
Institute on Drug Abuse (NIDA) Summer
Research Internship Program—0925–
0738—expiration date, 12/31/2022,
EXTENSION, National Institute on Drug
Abuse (NIDA), National Institutes of
Health (NIH).
Need and Use of Information
Collection: The purpose of the proposed
information is for the selection of
interns for the continuing NIDA
Summer Research Internship Program.
This request is to allow NIDA to collect
information from applicants in order to
meet the goals of the program and IC
mission. Applicant eligibility for this
program is open to those 18 and over in
the year of application per NIH policy
document 2022 Summer Research
Internship Program (NIDA–SRIP) Policy.
NIDA will request clearance for any
additional forms should new programs
be introduced in the future.
The information ensures that students
applying to this program meet basic
eligibility requirements; indicates their
interest in substance abuse research,
future career goals, and, if selected for
the program, what research they prefer
to conduct. The information also
enables decision-making regarding
which applicants will be selected for
internships. In each case, completing
the application is voluntary, but in
order to receive due consideration, the
prospective applicant must complete all
fields required by the program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
300.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Wilson
Compton, Acting Director, Office of
Research Training, Diversity and
Disparities, 3WFN, 11601 Landsdown
St., Room 09D18, North Bethesda,
Maryland, 20892 or call non-toll-free
number (301) 443–6480 or Email your
request, including your address, to:
Wilson.Compton@nih.gov.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on October 21, 2022, page
64068 (87 FR 64068) and allowed 60
days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment.
The National Institute on Drug Abuse
(NIDA), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
ADDRESSES:
TKELLEY on DSK125TN23PROD with NOTICE
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hour
Form name
Type of respondent
Summer Internship ............................
Individuals—household ....................
300
1
1
300
Total ...........................................
...........................................................
........................
300
........................
300
VerDate Sep<11>2014
20:36 Dec 22, 2022
Jkt 259001
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
E:\FR\FM\23DEN1.SGM
23DEN1
78988
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
Dated: December 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27990 Filed 12–22–22; 8:45 am]
[FR Doc. 2022–27956 Filed 12–22–22; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
Dated: December 20, 2022.
Lanette A. Palmquist,
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
TKELLEY on DSK125TN23PROD with NOTICE
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Technologies to Improve Delivery
of Pharmacological, Gene Editing, and Other
Cargoes for HIV and SUD Mechanistic or
Therapeutic Research.
Date: January 25, 2023.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577 caitlin.moyer@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
VerDate Sep<11>2014
21:35 Dec 22, 2022
Jkt 259001
Request for comments on the initial
revised draft of the Update to the
Certified Community Behavioral Health
Clinics certification criteria
Substance Abuse and Mental
Health Services Administration.
ACTION: Request for Comments on the
Initial Revised Draft of the Update to the
Certified Community Behavioral Health
Clinics Certification Criteria.
AGENCY:
SAMHSA is seeking public comment
on the initial revised draft of the update
to the Certification Criteria for Certified
Community Behavioral Health Clinics
(CCBHCs). CCBHCs were established
under the Section 223 of the Protecting
Access to Medicare Act of 2014 (PAMA,
Pub. L. 113–93). Section 223 of PAMA
requires the establishment of Medicaid
demonstration programs to improve
community behavioral health services
through the development of CCBHCs.
CCBHCs are required to provide a
comprehensive array of coordinated
services to anyone who requests care for
mental health or substance use,
regardless of ability to pay, place of
residence, or age—including
developmentally appropriate care for
children. PAMA required the
Department of Health and Human
Services (HHS) to develop criteria for
states to use when certifying clinics to
participate in their demonstration
programs. These criteria include six
areas: (1) staffing, (2) availability and
accessibility of services, (3) care
coordination, (4) scope of services, (5)
quality and other reporting, and (6)
organizational authority. The current
Certification Criteria can be found at:
https://www.samhsa.gov/sites/default/
files/programs_campaigns/ccbhccriteria.pdf.
There have been significant
developments in the CCBHC program
and in the broader mental health and
substance use disorder field since the
development of the existing
Certification Criteria. States and
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
providers now have six years of
experience with the CCBHC model and
lessons learned related to the
implementation of the Certification
Criteria. SAMHSA is seeking to make
minor revisions to the Criteria to
respond to these developments and
lessons learned, while still maintaining
the overarching requirements for
program areas and scope of services
outlined in PAMA.
To develop the initial draft of the
updated CCBHC Criteria, SAMHSA
gathered input in several ways. Public
opportunities for input were posted on
https://www.samhsa.gov/certifiedcommunity-behavioral-health-clinics/
ccbhc-criteria-update-announcements.
Public meeting dates and virtual
locations were disseminated through
SAMHSA listservs. On November 17,
2022, SAMHSA held a virtual public
listening session open to the public to
provide input on the existing CCBHC
Criteria. SAMHSA also accepted written
input from the public and stakeholders
sent to ccbhccriteria@samhsa.hhs.gov
by November 21, 2022. In addition to
public outreach, SAMHSA also received
feedback on potential revisions to the
existing CCBHC Criteria from key
stakeholders and federal partners.
The initial draft of the updated
CCBHC Criteria will be available for
public comment before the end of
December 2022 and will be open to midJanuary 2023. Information on CCBHC
Criteria updates and the process to
support them is available at: https://
www.samhsa.gov/certified-communitybehavioral-health-clinics/ccbhc-criteriaupdate-announcements. The posting of
the initial draft of the updated CCBHC
Criteria will also be announced through
SAMHSA’s listserv, CCBHC Training
and Technical Assistance grant
program, and CCBHC State Technical
Assistance contract. SAMHSA requests
all comments to the initial draft of the
updated CCBHC Criteria be sent to
ccbhccriteria@samhsa.hhs.gov.
Authority: Section 223 of the
Protecting Access to Medicare Act
(2014), as amended.
Contact: Mary Blake, Substance
Abuse and Mental Health Services
Administration, 5600 Fishers Lane,
Rockville, MD 20857, telephone (240)
276–1747; email: mary.blake@
samhsa.hhs.gov.
Alicia Broadus,
Public Health Advisor.
[FR Doc. 2022–28028 Filed 12–22–22; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\23DEN1.SGM
23DEN1
]]>Agencies
[Federal Register Volume 87, Number 246 (Friday, December 23, 2022)]
[Notices]
[Pages 78987-78988]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27990]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request: National
Institute on Drug Abuse (NIDA) Summer Research Internship Program
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has submitted to the Office of
Management and Budget (OMB) a request for review and approval of the
information collection listed below.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 30-days of the date of
this publication.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact: Dr. Wilson Compton, Acting Director, Office of
Research Training, Diversity and Disparities, 3WFN, 11601 Landsdown
St., Room 09D18, North Bethesda, Maryland, 20892 or call non-toll-free
number (301) 443-6480 or Email your request, including your address,
to: [email protected].
SUPPLEMENTARY INFORMATION: This proposed information collection was
previously published in the Federal Register on October 21, 2022, page
64068 (87 FR 64068) and allowed 60 days for public comment. No public
comments were received. The purpose of this notice is to allow an
additional 30 days for public comment.
The National Institute on Drug Abuse (NIDA), National Institutes of
Health, may not conduct or sponsor, and the respondent is not required
to respond to, an information collection that has been extended,
revised, or implemented on or after October 1, 1995, unless it displays
a currently valid OMB control number.
In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction
Act of 1995, the National Institutes of Health (NIH) has submitted to
the Office of Management and Budget (OMB) a request for review and
approval of the information collection listed below.
Proposed Collection: National Institute on Drug Abuse (NIDA) Summer
Research Internship Program--0925-0738--expiration date, 12/31/2022,
EXTENSION, National Institute on Drug Abuse (NIDA), National Institutes
of Health (NIH).
Need and Use of Information Collection: The purpose of the proposed
information is for the selection of interns for the continuing NIDA
Summer Research Internship Program. This request is to allow NIDA to
collect information from applicants in order to meet the goals of the
program and IC mission. Applicant eligibility for this program is open
to those 18 and over in the year of application per NIH policy document
2022 Summer Research Internship Program (NIDA-SRIP) Policy. NIDA will
request clearance for any additional forms should new programs be
introduced in the future.
The information ensures that students applying to this program meet
basic eligibility requirements; indicates their interest in substance
abuse research, future career goals, and, if selected for the program,
what research they prefer to conduct. The information also enables
decision-making regarding which applicants will be selected for
internships. In each case, completing the application is voluntary, but
in order to receive due consideration, the prospective applicant must
complete all fields required by the program.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 300.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Type of Number of Number of burden per Total annual
Form name respondent respondents responses per response (in burden hour
respondent hours)
----------------------------------------------------------------------------------------------------------------
Summer Internship............. Individuals--hou 300 1 1 300
sehold.
---------------------------------------------------------------
Total..................... ................ .............. 300 .............. 300
----------------------------------------------------------------------------------------------------------------
[[Page 78988]]
Dated: December 20, 2022.
Lanette A. Palmquist,
Project Clearance Liaison, National Institute on Drug Abuse, National
Institutes of Health.
[FR Doc. 2022-27990 Filed 12-22-22; 8:45 am]
BILLING CODE 4140-01-P
